Home / Health / Perth Biotech Paves Way for One-Patient Medicines
Perth Biotech Paves Way for One-Patient Medicines
19 Nov
Summary
- Syngenis Labs partners with WA institutes for rare genetic disease treatments.
- New platform aims to speed up safety testing for experimental RNA medicines.
- Company is building Australia's first GMP facility for oligonucleotide manufacturing.

Syngenis Labs, a Perth biotechnology firm, is forging partnerships with the Perron Institute and the Personalised Medicine Centre (PMC) to advance treatments for children with rare genetic diseases. This collaboration establishes a specialized preclinical safety-testing platform for experimental RNA medicines targeting neurological conditions.
The initiative aims to address the significant challenge of confirming the safety of novel drug candidates before human trials. Syngenis, founded in 2020, manufactures specialized genetic materials, including oligonucleotides, used in disease research and experimental medicine development.
The new safety-testing platform, located at the PMC, will integrate laboratory testing and in-vivo studies. This approach is expected to accelerate the identification of potential safety issues and reduce costs and delays in bringing promising treatments to patients.
This effort is bolstered by substantial investment in Western Australia's rare-disease research sector. The Perron Institute, a long-established neuroscience research center, is a strategic shareholder in Syngenis. Additionally, the Stan Perron Charitable Foundation has committed $221 million over ten years to the Rare Care Comprehensive Centre.
Syngenis is also constructing Australia's first Good Manufacturing Practice (GMP) facility for clinical-grade oligonucleotide manufacturing, with targeted regulatory approval in 2027. This facility will support the entire development chain, from research to clinical trials, aiming to reduce Australia's reliance on overseas drug development resources.
The company's investment arm, Syngenis Ventures, also holds a stake in Gene-S Dx, which uses genetic information to tailor existing medicines and dosages to individual patients. These combined initiatives position Syngenis at the forefront of personalized medicine, addressing both the development of new treatments and optimizing the use of existing ones.